Current and future therapies for hepatitis C virus infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review.World journal of hepatology · 2022
   Review
2. Entry Inhibitors of Hepatitis C Virus.Advances in experimental medicine and biology · 2022
   Article
3. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.International journal of general medicine · 2021
   Review
4. Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.Hepatology (Baltimore, Md.) · 2018
   Article
5. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.Molecular diagnosis & therapy · 2018
   Review
6. Undiagnosed HIV and HCV Infection in a New York City Emergency Department, 2015.American journal of public health · 2018
   Article
7. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.Canadian journal of gastroenterology & hepatology · 2018
   Article
8. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.American journal of public health · 2017
   Article
9. Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016
   Article
10. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection.Journal of clinical and translational hepatology · 2016
    Review
11. Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies.North American journal of medicine & science · 2016
    Article
12. Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.The Indian journal of medical research · 2016
    Article
13. Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.Drug design, development and therapy · 2016
    Review
14. Finding a cure for human immunodeficiency virus-1 infection.Infectious disease clinics of North America · 2014
    Review
15. Rising Trends in Emergency Department Visits Associated With Hepatitis C Virus Infection in the United States, 2006-2014.Public health reports (Washington, D.C. : 1974)
    Article
16. Liver Transplantation Update: 2014.Euroasian journal of hepato-gastroenterology
    Review

Corrections and comments

• Comment on
  Current and future therapies for hepatitis C virus infection.2013
• Comment on
  Current and future therapies for hepatitis C virus infection.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as